Survival and graft function in a large animal lung transplant model after 30 h preservation and substitution of the nitric oxide pathway by Hillinger, Sven et al.
Survival and graft function in a large animal lung transplant model after
30 h preservation and substitution of the nitric oxide pathwayq
Sven Hillingera, Peter Sanderab, Giovanni L. Carbonib, Uz Stammbergerb, Marco Zalunardoc,
Gabriele Schoedond, Ralph A. Schmidb,*
aDivision of General Thoracic Surgery, University Hospital ZuÈrich, ZuÈrich, Switzerland
bDivision of General Thoracic Surgery, University Hospital Bern, Bern, Switzerland
cDepartment of Anesthesiology, University Hospital ZuÈrich, ZuÈrich, Switzerland
dDepartment of Internal Medicine, University Hospital ZuÈrich, ZuÈrich, Switzerland
Received 11 October 2000; received in revised form 2 May 2001; accepted 22 May 2001
Abstract
Objective: Substitution of the nitric oxide- (NO-) pathway improves early graft function following lung transplantation. We previously
demonstrated that 8-Br-cGMP (second messenger of NO) to the ¯ush solution and tetrahydrobiopterin (BH4, coenzyme of NO synthase)
given as additive during reperfusion improve post-transplant graft function. In the present study, the combined treatment with 8-Br-cGMP
and BH4 was evaluated. Methods: Unilateral left lung transplantation was performed in weight matched outbred pigs (24±31 kg). In group I,
grafts were preserved for 30 h n  5. 8-Br-cGMP (1 mg/kg) was added to the ¯ush solution (Perfadexe, 1.5 l, 18C) and BH4 (10 mg/kg/h)
was given to the recipient for 5 h after reperfusion. In group II, lungs were transplanted after a preservation time of 30 h n  3 and
prostaglandin E1 (250 g) was given into the pulmonary artery (PA) prior to ¯ush. In all recipients 1 h after reperfusion the contralateral right
PA and bronchus were ligated to assess graft function only. Survival time after reperfusion, extravascular lung water index (EVLWI),
hemodynamic variables, and gas exchange (PaO2) were assessed during a 12 h observation period. Results: All recipients in group I survived
the 12 h assessment, whereas none of the group II animals survived more than 4 h after reperfusion with a rapid increase of EVLWI up to
24.8 ^ 6.7 ml/kg. In contrast, in group I EVLWI reached up to 8.9 ^ 1.5 ml/kg and returned to nearly normal levels at 12 h (6.1 ^ 0.8 ml/
kg). In two animals of group I the gas exchange deteriorated slightly. The other three animals showed normal arterial oxygenation over the
entire observation time. Conclusion: Our data indicate that the combined substitution of the NO pathway during preservation and reperfusion
reduces ischemia/reperfusion injury substantially and that this treatment even allows lung transplantation after 30 h preservation in this
model. q 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Endothelial dysfunction plays a key role in ischemia/
reperfusion injury following organ transplantation and
results in reduced production of nitric oxide (NO). NO
protects the endothelium and antagonizes vasoconstrictive
and thrombogenic substances as endothelin-1, platelet-acti-
vating factor, oxygen free radicals, or hypoxia [1]. The
balance of protective and proin¯ammatory agents deter-
mines endothelial cell integrity during reperfusion after
pulmonary ischemia. NO is essential for numerous endothe-
lium-dependent mechanisms such as vasodilation, modula-
tion of neutrophil adhesion, and platelet aggregation, as well
as for the maintenance of endothelial barrier properties [2].
During reperfusion, the NO availability is reduced and the
lack of NO accelerates graft dysfunction. It may be substi-
tuted by the application of NO donors, by NO inhalation, or
by the substitution of other steps of the NO synthesis (Fig.
1). However, most of these methods are not suitable for
clinical application.
In previous studies, we demonstrated that the 8-Br-
cGMP, a membrane permeable analogue of cGMP, or tetra-
hydrobiopterin (BH4), an essential coenzyme of the NO
synthases (NOSs), either given in the ¯ush or during reper-
fusion improves post-transplant graft function. Addition of
the 8-Br-cGMP to the ¯ush solution [3] was superior to
continuous infusion of the analogue during reperfusion
[4]. Furthermore, continuous treatment of the recipient
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with BH4 during the ®rst hours after reperfusion increased
pulmonary venous cGMP up to ten-fold and improved graft
function impressively [5].
As a consequence of these experiments, we evaluated the
effect of combined treatment with the 8-Br-cGMP as addi-
tive to the ¯ush solution and continuous infusion of BH4 to
the recipient during reperfusion on early graft function in a
large animal model of unilateral lung transplantation.
2. Materials and methods
Eleven weight matched pairs of outbred pigs served as
donors and recipients. Harvest and left lung transplantation
were performed as previously reported [3±6]. Lungs were
¯ushed with 1.5 l of low potassium dextran (LPD) solution
(Perfadex, generously provided by XVIVO AB, Uppsala,
Sweden) and stored at a temperature of 18C for 30 or 6 h,
respectively. One hour after reperfusion, the right contral-
ateral lung was excluded from perfusion and ventilation. All
animals received humane care in compliance with the
European Convention on Animal Care. The protocol was
approved by the local animals study commitee.
2.1. Study groups
Three groups were studied. In group I n  5, 8-Br-
cGMP (1 mg/kg, Sigma Chemicals, Switzerland) was
added to the ¯ush solution. In addition, BH4 (10 mg/kg/h,
intravenously (i.v.)) was given to the recipient as continuous
infusion for 5 h after reperfusion, starting 15 min before
reperfusion. In group II n  3, 8 mg/kg prostaglandin E1
(PGE1) (Prostin VR Pediatric, The Upjohn Company, Kala-
mazoo, MI, USA) was injected directly into the main
pulmonary artery (PA) before the ¯ush as in clinical use.
Preservation time of groups I and II donor lungs was 30 h.
As additional control group (group III), three animals were
transplanted after 6 h of cold ischemic preservation, and
PGE1 (8 mg/kg) was given prior to ¯ush as in group II.
2.2. Assessment
One hour after reperfusion of the transplanted lung the
right pulmonary arteries and the right main bronchus were
ligated to assess allograft function for the ®rst 12 h after
reperfusion. During the assessment period, anesthesia was
maintained with ¯uothane 1.5%. FiO2 was 100%, the venti-
lation volume 5.5 l at a respiratory rate of 20 per min and a
positive endexspiratory pressure (PEEP) of 5 mm H2O.
Systemic arterial, PA, central venous, and left atrial pressure
were recorded continuously. Arterial and mixed venous
blood were collected for gas analysis every 60 min.
At the end of the observation period, 12 h after reperfu-
sion, the animals were sacri®ced. In group I and group III
animals that survived the entire assessment, the upper lobe
allograft samples were submitted to histologic examination,
tissue myeloperoxidase (MPO), and thiobarbituric acid-
reactive substance (TBARS) assay. Normal lung tissue
was excised from the ¯ushed upper lobe of each donor,
snap frozen and assessed as the allograft samples.
All values are given as the mean ^ standard deviation (in
the ®gures standard error) of the mean (SEM).
2.3. Extravascular lung water (EVLW)
EVLW as direct assessment of reperfusion edema was
measured as previously described [6]. A ®beroptic catheter
(System Cold Z-021, Pulsion, Munich, Germany) is
advanced via the external carotid artery into the descending
aorta. The indicator bolus consists of two components: indo-
cyanine green serves as intravascular marker and ice cold
5% glucose as a thermal intra- and extravascular indicator.
The bolus is injected via the external jugular vein with a
temperature-controlled injector. The dilution curves for dye
and temperature are recorded simultaneously in the
descending aorta with the thermistor tipped ®beroptic cathe-
ter. Thoracic intra- and extravascular ¯uid volumes are
determined based on the measurement of the mean transit
times for thermal and dye indicators and of the decay time
volumes calculated from the indicator dilution curves. The
lung water computer (System Cold Z-021, Pulsion, Munich,
Germany) determines the mean transit time for the thermal
indicator and for the dye indicator and calculates total ther-
mal volume (ITTV), intrathoracic blood volume (ITBV),
and extravascular thermal volume (ETV). The ETV is
calculated as follows: ETV  ITTV 2 ITBV. All measure-
ments were made in triplicate. The mean value was used for
analysis.
2.4. MPO assay
Donor and recipient lung samples were frozen immedi-
ately and stored at 2808C until assay. Quantitative MPO
activity was determined using routine methods as
previously described [6]. The frozen lung tissue (100 mg)
was homogenized in 1 ml of 0.5% hexadecyltrimethyl-
ammonium bromide, 5 mmol/l EDTA, and 50 mmol/l
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Fig. 1. NO pathway [22]. BH4 is an essential coenzyme of the NOSs, 8-Br-
cGMP a non-toxic membrane permeable cGMP analogue.
potassium phosphate buffer (pH 6.2) with a tissue grinder.
The homogenate was centrifuged at 10 000 £ g for 15 min
at 48C. The supernatant was assayed for total soluble protein
and MPO activity. Enzyme activity was measured spectro-
photometrically. Five-fold supernatant (10 mg) was
combined with 0.6 ml Hank's bovine serum albumin
(BSA), 0.5 ml of 100 mmol/l potassium phosphate buffer
(pH 6.2), 0.1 ml 0.05% H2O2, and 0.1 ml of 1.25 mg/ml o-
dianisidine. The reaction was stopped by the addition of 1%
NaN3 after 5 and 20 min, respectively, at room temperature.
The optical density was measured at 460 nm with a spectro-
photometer (Kadas 100, Dr Lange AG, Zurich, Switzer-
land). Color development from 5 to 20 min was linear.
Enzyme activity is expressed as change in optical density
units per milligram of tissue protein per minute (DOD/mg/
min).
2.5. TBARS assay
TBARS levels in lung tissue were measured with 10%
wet weight per volume homogenate [6]. Aliquots (0.2 ml) of
this homogenate were added to tubes containing 0.2 ml of
8.1% sodium dodecyl sulfate, 1.5 ml of 20% acetic acid
solution adjusted to pH 3.5 with NaOH, and 1.5 ml of
0.8% solution of thiobarbituric acid. The mixture was
brought to a volume of 4 ml by the addition of distilled
water, heated at 958C for 60 min, and then cooled with tap
water. Distilled water (1 ml) and 5 ml of butanol/pyridine
(15:1) were added (all chemicals by Fluka AG, Switzer-
land). The solution was centrifuged at 4000 rpm for
10 min. The absorbance of the upper layer was measured
at 532 nm with a spectrophotometer (Kadas 100, Dr Lange
AG, Zurich, Switzerland). The TBARS levels were deter-
mined by reference to a standard curve of 1,1,3,3-tetra-
methoxypropane (Sigma Chemicals, Buchs, Switzerland),
and the results were expressed as picomoles of malondial-
dehyde (MDA) per gram of wet lung.
2.6. Hemodynamic parameters and gas exchange
Systemic arterial, PA, central venous, and left atrial pres-
sure were recorded continuously with a hemodynamic
monitor system (Hellige, Freiburg, Germany). Measure-
ment of cardiac output is necessary for the lung water
assessment (System Cold Z-021, Pulsion, Munich,
Germany). Pulmonary vascular resistance (PVR) was calcu-
lated according to the formula PVR  80 £ MPAP 2
PCWP=CO (MPAP, mean pulmonary arterial pressure;
PCWP, pulmonary capillary wedge pressure; CO, cardiac
output). Arterial and mixed venous blood were collected for
gas analysis every 60 min. For assessment of PaO2, an auto-
matic blood gas analyzer (AVL 993, AVL List GmbH,
Graz, Austria) was used.
3. Results
3.1. Characteristics of experimental groups
No differences between the groups were noted in donor
weight (group I 29.3 ^ 2.5 vs. group II 27.7 ^ 3.1 vs. group
III 28.6 ^ 1.6 kg), recipient weight (group I 28.7 ^ 2.7 vs.
group II 27 ^ 2.8 vs. group III 26.5 ^ 0.5 kg), and warm
ischemic time (group I 70 ^ 7 vs. group II 67 ^ 5; group III
66 ^ 7 min). Total preservation time did not differ in group
I and group II (group I 30.01 ^ 0.3 vs. group II
29.98 ^ 0.43; group III 5.86 ^ 0.07 h).
3.2. Survival
In treatment group I, all ®ve recipients survived the 12 h
assessment period with good pulmonary function. In control
group II, two animals died within 2 h, and one 3 h after
occlusion of the right native lung developing severe
pulmonary edema and subsequent right heart failure. In
control group III all recipients survived the entire procedure.
3.3. Reperfusion edema
Extravascular lung water index (EVLWI) in the allografts
of group I animals rose to 8.9 ^ 3.4 ml/kg and returned to
nearly normal levels at the end of the assessment
(6.1 ^ 1.8 ml/kg). In group II animals, EVLWI showed a
rapid increase up to 24.8 ^ 11.6 ml/kg. In group III, normal
levels of EVLWI (5 ^ 1.7 ml/kg) were measured over the
entire observation period (Fig. 2).
3.4. Gas exchange and hemodynamic parameters
In two of the treated recipients the gas exchange deterio-
rated slightly. The other three animals showed normal arter-
ial oxygenation over the entire observation time (Fig. 3).
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Fig. 2. EVLW as measurement for pulmonary edema. EVLW in the treated
pulmonary allografts (group I) rose to 8.9 ^ 1.5 ml/kg and returned to
nearly normal levels at the end of the assessment (6.1 ^ 0.8 ml/kg). None
of the untreated animals with grafts preserved for 30 h (group II) survived
more than 4 h after reperfusion with a rapid increase of EVLWI up to
24.8 ^ 6.7 ml/kg (mean ^ SEM).
The PVR increased at the time of exclusion of the right
native lung in all groups. In groups I and III, the PVR
remained constant during the assessment at levels around
700±800 dyn/s/cm25 in contrast to group II animals, in
which the PVR rose to values over 1000 dyn/s/cm25 (Fig.
4).
3.5. Neutrophil migration
Allograft MPO activity 12 h after reperfusion was
comparable in groups I and III (group I 2.2 ^ 0.4 vs.
group III 2.3 ^ 0.7 DOD/mg/min). The MPO activity in
normal ¯ushed lung tissue (snap frozen without storage)
was 0.5 ^ 0.2 DOD/mg/min (Fig. 5).
3.6. Lipid peroxidation
Free radical tissue damage expressed as MDA concentra-
tion per gram wet lung was not different between groups I
and III (group I 69.2 ^ 37.8 vs. group III 50.2 ^ 27.9 pmol/
g). The MDA concentration in normal lung tissue (snap
frozen without storage) was 43 ^ 10.1 pmol/g (Fig. 6).
4. Discussion
NO substitution with 8-Br-cGMP in the ¯ush solution and
BH4 given during reperfusion allows lung transplantation
after 30 h of graft preservation in this model. The injury in
the treated grafts was comparable to that of the control
group with a preservation time of 6 h. None of the untreated
animals with 30 h preservation time survived more than 4 h
after reperfusion and all showed rapid development of
severe reperfusion injury.
Ischemia and reperfusion are accompanied by an intra-
cellular decrease of cAMP and cGMP. cAMP is the second
messenger of PG and cGMP of NO. Both mediate vasodila-
tion and play a major role in the modulation of the vascular
tone in the lung, as well as in the regulation of the endothe-
lial permeability and neutrophil adhesivity [2]. Our previous
study [3], in accordance with the study of Bhabra et al. [7],
suggests that the substitution of the NO/cGMP pathway is
more important than substitution of the PG/cAMP pathway.
A series of experiments shows that the enhancement of
local NO levels improves organ function after lung trans-
plantation [1,2,8,9]. NO has been substituted in experimen-
tal or clinical studies by the administration of exogenous l-
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Fig. 4. PVR increased at the time of exclusion of the right native lung, but
the changes were similar between treated animals (group I) and 6 h controls
(group III) (mean ^ SEM).
Fig. 5. Polymorphnuclear lymphocytes (PMN) migration measured as MPO
activity in the graft tissue of surviving recipients shows similar levels in the
treated animals (group I) and 6 h controls (group III) at the end of the
assessment. Normal, normal ¯ushed lung tissue (mean ^ SEM).
Fig. 6. Lipid peroxidation in the graft tissue of surviving recipients as
measurement for the free radical injury. TBARS levels in the allograft
12 h after reperfusion were comparable between the survivors (groups I
and III) (mean ^ SEM).
Fig. 3. Arterial oxygenation (PaO2) over the ®rst 12 h. In two of the treated
recipients the gas exchange deteriorated slightly. The other three animals
showed normal arterial oxygenation over the entire observation time (group
I) (mean ^ SEM).
arginine [10], NO donors [11], or NO inhalation [12,13].
Application of the NO donors is mainly limited by systemic
side effects (e.g. hypotension). NO inhalation is used in a
wide area of clinical settings to reduce ischemia reperfusion
injury; however, the application in clinical practice is tech-
nically cumbersome and expensive. Therefore, we devel-
oped new strategies to substitute the NO pathway in lung
transplantation.
BH4 has speci®c properties to qualify as the limiting step
for NO synthesis in dysfunctional endothelium following
ischemia and reperfusion. It increases the af®nity of NOS
to l-arginine [14], it stabilizes NOSs [15], and it inhibits the
negative feedback of NO on NOSs [16]. In the absence of
BH4, NOSs no longer produce NO, but catalyze reactions
leading to oxygen free radical production [17]. In addition,
BH4 has a very low toxicity [18] and can be administered
even in high doses simply by the i.v. route.
8-Br-cGMP is a non-toxic membrane permeable and
enzyme resistant analogue of cGMP with equal biological
effects and has been used previously to reduce ischemia/
reperfusion injury [2,3,19±21].
The two substances, 8-Br-cGMP and BH4, were applied
based on the following theoretical re¯ections. During perfu-
sion with the cold preservation solution, temperature in the
graft decreases rapidly and therefore stimulation of NO
synthesis with substrates of NOS seems to be useless, but
the administration of cGMP as `second messenger' of NO
can be applied in the ¯ush solution and is effective in the
very early phase of reperfusion. Supplementation of the
BH4 during reperfusion increases the NO synthesis;
however, this accelerated NO synthesis is still regulated
endogenously, and side effects of exogenous NO may be
avoided. The BH4 even seems to be suitable for clinical
application as it has a long half-life and an extremely low
toxicity [18].
Pinsky et al. showed that intracellular cGMP levels
decrease sharply at the time of reperfusion. The constitu-
tional NO synthase (cNOS) itself remains essentially unaf-
fected by either preservation and reperfusion; however, NO
production is decreased and consumption during reperfu-
sion is increased due to rapid reaction of NO with oxygen
free radicals [2]. A `saturation' with cGMP during the ¯ush
and enhancement of NO production in the ®rst phase of
reperfusion would be the logical conclusion.
Survival of the animals after reperfusion demonstrates
clearly that a preservation time of 30 h in the control
group without treatment did not result in suf®cient graft
function. We therefore decided to limit the number of
animals in the control groups.
The intragroup variety in arterial oxygenation in the trea-
ted recipients of group I (Fig. 3) con®rms our hypothesis
from former studies that the gas exchange is not a good
parameter to assess lung injury in this model. In spite of
the fact that PaO2 in many studies is used as the main para-
meter for reperfusion injury, the lung water computer
employed in this model allows us to assess hemodynamic
parameters and the dynamic changes of the lung edema very
precisely.
We employed an observation period of 12 h after reper-
fusion to observe changes after the 5 h treatment with BH4.
No deterioration of lung function after cessation of the BH4
infusion was noted, which underlines the important role of
NO in the early phase after reperfusion. Lung edema in
animals with NO substitution increased slowly over the
®rst 5 h after reperfusion. In contrast to untreated animals,
after only 20 h preservation, the peak of pulmonary edema
was already reached 2±3 h after reperfusion [3±5]. From the
present study and from previous experiments with the aim
of optimizing strategies to enhance NO in lung transplanta-
tion, we could conclude that substitution of the NO pathway
during both preservation and reperfusion is important.
Our data con®rm that combined substitution of the NO
pathway during preservation and reperfusion reduces ische-
mia/reperfusion injury, and indicates that the treatment with
8-Br-cGMP and BH4 seems to allow prolongation of the
preservation time to 30 h in this model. This strategy may
open new perspectives for clinical lung transplantation.
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